Pharmacy Clinical Policy Bulletins Aetna Medicare Prescription Drug Plan
Subject: Diuretics
Status
Drug
PR-B/D
PR
PR-QL
PR-AL
ST
M EX‡
TOC§
C
amiloride
C
bumetanide
C
chlorothiazide
C
chlorthalidone
C
furosemide
C
hydrochlorothiazide (HCTZ)
C
indapamide
C
methyclothiazide
C
metolazone
C
spironolactone
C
spironolactone/HCTZ
C
torsemide
C
amilodride/HCTZ
C
triamterene/HCTZ
NC
Aldactone®(spironolactone)
X
NC
Bumex®(bumetanide)
X
NC
Demadex®(torsemide)
X
NC
Dyrenium®(triamterene)
X
NC
Dyazide®(triamterene/HCTZ)
X
NC
Edecrin®(ethacrynic acid)
X
NC
Enduron®(methyclothiazide)
X
NC
Inspra®(eplerenone)
X
NC
Lasix®(furosemide)
X
NC
Lozol®(indapamide)
X
NC
Maxzide®(triamterene/HCTZ)
X
NC
Midamor®(amiloride)
X
NC
Moduretic®(amilodride/HCTZ)
X
NC
Naturetin®(bendroflumethiazide)
X
NC
Zaroxolyn®(metolazone)
X
Policy:
Medical Exception Criteria
Aldactone, Bumex, Demadex, Dyrenium, Dyazide, Edecrin, Enduron, Inspra, Lasix, Lozol, Midamor, Moduretic, Maxzide, Naturetin, and Zaroxolyn are currently Not Covered Part D drugs under the Aetna Medicare Prescription Drug Plan.* Therefore, they are excluded from coverage for members enrolled in prescription drug benefit plans that use a closed formulary, unless a medical exception is granted. Aetna considers Aldactone, Bumex, Demadex, Dyrenium, Dyazide, Edecrin, Enduron, Inspra, Lasix, Lozol, Midamor, Moduretic, Maxzide, Naturetin, and Zaroxolyn to be medically necessary for those members who meet the criteria as specified below:
For Aldactone, Bumex, Demadex, Dyazide, Enduron, Lasix, Lozol, Maxzide, Midamor, Moduretic and Zaroxolyn
A. A documented:
Intolerance to the equivalent preferred generic diuretic OR
Contraindication to the equivalent preferred generic diuretic OR
Allergy to the equivalent preferred generic diuretic OR
Failure of an adequate trial of one month of the equivalent preferred generic diuretic
For Dyrenium, Edecrin and Naturetin
A. A documented:
Intolerance to two preferred diuretics indicated for the member's condition OR
Contraindication to two preferred diuretics indicated for the member's condition OR
Allergy to two preferred diuretics indicated for the member's condition OR
Failure of an adequate trial of one month each of two preferred diuretics indicated for the member's condition
For Inspra
A. A documented:
Intolerance to the preferred diuretic spironolactone OR
Contraindication to the preferred diuretic spironolactone OR
Allergy to the preferred diuretic spironolactone OR
Failure of an adequate trial of the preferred diuretic spironolactone
* Coverage is provided through a Medicare Prescription Drug Plan Sponsor with a Medicare contract and benefits, limitations, service areas and premiums are subject to change on January 1 of each year.
Place of Service:
Outpatient
The above policy is based on the following references:
Brenner & Rector's The Kidney, Sixth Edition, 2000 W. B. Saunders Company, Chapter 53 Diuretics p 2219-2252.
Goldman: Cecil Textbook of Medicine, 21st Ed., W. B. Saunders Company, 2000.
Stein JH, Wilson CB & Kirkendall WM: Differences in acute effects of furosemide and ethacrynic acid in man. J Lab Clin Med 1968; 71:654-665.
Biro L & Szebenyi A: Diuretic treatment in congestive heart failure with Uregyt (ethacrynic acid). Ther Hung 1971; 19(1):33-37.
Olesen KH: A comparison of the diuretic action of mercaptomerin, ethacrynic acid, and furosemide in congestive heart failure. Acta Med Scand 1970; 187(5):391-399.
Stone AM & Stahl WM: Effects of ethacrynic acid and furosemide in renal function in hypovolemia. Ann Surg 1971; 174(1):1-11.
Krueck F: Acute and long term effects of loop diuretics in heart failure. Drugs 1991; 41(suppl 3):60-68.
Russo D, Minutolo R & Andreucci VE: Role of loop diuretics in chronic renal failure. Cardiology 1994; 84(suppl 2):162-170.
Ellison DH, Wilcox CS: Diuretic resistance. In Brady HR, Wilcox CS (eds): Therapy in Nephrology and Hypertension. WB Saunders, Philadelphia, 1999
Voelker JR, Cartwright Brown D, Anderson S, et al: Comparison of loop diuretics in patients with chronic renal insufficiency. Kidney Int 32:572-578, 1987
Guideline Committee for the Heart Failure Society of America. HSFA guidelines for the management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. CHF 2000;6:11-29.
Wright JM, Lee CH, Chambers GK. Systematic review of antihypertensive therapies: Does the evidence assist in choosing a first-line drug? CMAJ 1999;161:25-32.
Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N EngI J Med 1993;328:914-21.
Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, et al, for the Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study. Final results. JAMA 1993;270:713-24.
Morrison RT. Renal Disease. Edema and principles of diuretic use. Med Clin North Am 1997;81:689-704.
Schrier RW, Abdallah JG, Weinberger HH, Abraham WT. Therapy of heart failure. Kidney Int 2000;57(4):1418-25.
Neal B and MacMahon S. An overview of 37 randomized trials of blood pressure lowering agents among 270,000 individuals. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. Clin Exp Hypertens 1999;21(5-6):517-29.
USPDI Drug Information for the HealthCare Professional (online). Thomson MICROMEDEX, Greenwood Village, Colorado; 2004.
McEvoy GK, editor. AHFS Drug Information (online). American Society of Health-Systems Pharmacists, Bethesda, Maryland; 2004.
Olin BR, editor. Drugs Facts and Comparisons (electronic online version). St. Louis: J.B. Lippincott Company, 2004.
Medical Economics, Inc., PDR Electronic Library. Thomson Medical Economics, Montvale, NJ; 2004.
Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults. Arch Intern Med. 2003;163:2716-24.
Zahn C, Sangl J, Bierman AS, et al. Potentially inappropriate medication use in the community-dwelling elderly. JAMA. 2001;286:2823-29.
Property of Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.
*C = Covered, copay amount depends on benefits plan
NC = Not Covered Part D drug
PR-B/D = Precertification review criteria to determine coverage as Part B or Part D
PR = Precertification
QL = Quantity Limits
AL = Age Limits
ST = Step-Therapy
‡M EX = Medical Exception
§TOC = Transition of Coverage
*The lists above are subject to change. Not all programs - for example step-therapy, precertification, and quantity limits - are available in all service areas.